SK Hynix Shares Fall as Workers Reject Wage Deal 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Trump Buys SpaceX Shares After Record IPO 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Tesla Raises Cybertruck Prices by $5,000 in US 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Add as a preferred source on Google
HENDERSON, Nev., May 01, 2018 -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion. Both the expanded animal testing and human trials are being conducted to support the company’s HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA.
“After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed,” said Douglas K. Beplate, CEO, UHP. “We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA.”
About Premarket Approval (PMA): https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketapprovalpma/
About United Health Products, Inc.
United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464
